Intra-Cellular has had success selling Caplyta, a brain-rebalancing drug that's approved to treat schizophrenia and bipolar depression.

J&J said it would buy Intra-Cellular Therapies in a deal worth $14.6 billion, another sign of large drugmakers’ reentry into ...

Depression and anxiety are commonly experienced by people with chronic kidney disease (CKD). This study aimed to evaluate person- and service-level factors associated with depression and anxiety ...

Community treatment orders (CTOs) are legal provisions designed to prevent recidivism and improve the quality of life for ...

Reflecting on the progress made against coercive psychiatric practices and obtaining child protections in 2024, CCHR commits itself in 2025 to reinforcing the need to end psychiatric abuse, including ...

One or two doses of psilocybin, a compound found in psychedelic mushrooms, may improve the mental health of cancer patients when accompanied ... either vitamin B3 or a tiny dose of the psychedelic ...

After reinvigorating a decades-old schizophrenia drug in an innovative long-acting treatment option, Teva is looking to ...

A recent survey reveals a significant decline in teen drug and alcohol use since 2017, reaching its lowest point in 2024. Researchers attribute this drop to pandemic lockdowns disrupting social ...

After she started taking a popular medication used for weight loss and diabetes, she saw it as something else: food noise. “It’s so obsessive, and it’s not a good feeling. It’s a very ugly ...

Totaling several hundreds of dollars a month, the costs for these lifesaving medications were hopelessly out of reach of her salary as an early childhood educator. It was common for her ...

Other food interactions to ask about include leafy greens with certain blood thinners, dairy with tetracycline, and tyramine-containing foods (such as red wine and processed meat) with MAO inhibitors, ...